SEC Form 4 · accession 0001193125-26-266436
Axsome Therapeutics, Inc. · AXSM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark E Saad
Director
Period of report
Jun 8, 2026
Accepted (ET)
Jun 10, 2026 · 9:49 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001579428
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 8, 2026 | M | 1,429 | — | A | 11,431 | D | |
| Common StockF3 | holding | — | — | — | 300 | I | See Footnote. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2 | — | Jun 8, 2026 | M | 1,429 | D | — | — | Common Stock | 1,429 | 0 | D |
Explanation of responses
- F1On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant.
- F2Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- F3Represents additional shares held indirectly by the Reporting Person prior to June 10, 2026, which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.